Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK DH "confident for the NHS in the face of the economic downturn"

This article was originally published in Clinica

Executive Summary

In the face of the economic downturn, the UK government today said it was well placed to address the NHS' operational and supply funding needs. A predicted surplus of £1.73bn ($2.66bn) "will stay within the NHS and will be used to improve patient care", said the DH, citing its second-quarter (June-September 2008) performance report, published today. The DH is also forecasting a gross operating deficit of £86m at year-end, down from £125m at the end of 2007-08. Although the NHS, along with the rest of the public sector, "will have to make its contribution to delivering greater efficiency", the DH is "confident that [it is] well placed for the challenges ahead", said David Flory, director general for NHS Finance, Performance and Operations.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT043303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel